Abstracts, Posters, and Oral Presentations
Asia Pacific Society of Respirology (APSR) Congress 2022
Demographic and Clinical Characteristics of Patients with Severe Asthma in the Asian Pacific Region: data from the International Severe Asthma Registry (ISAR)
Juntao Lyu, et al.
This study describes the baseline demographic and clinical characteristics of severe asthma patients from 1326 patients of the Asia-Pacific countries in the International Severe Asthma Registry (ISAR). It highlights the inter-country heterogeneity in the characteristics of severe asthma patients in the Asia-Pacific region, potentially because of varied access to severe asthma services and treatments.
*Accepted as Oral presentation*
The European Respiratory Society (ERS) International Congress 2022
Effectiveness of initiating biologics in severe asthma patients with high steroid exposure (GLITTER)
Wenjia Chen, et al.
Real-world evidence on the effectiveness of therapeutic antibodies (“biologics”) in patients with asthma is limited. We aim to examine the effectiveness of initiating biologics in a large, international, real-world cohort of adult patients with severe asthma (SA) and high oral corticosteroid (OCS) exposure.
Biomarker-defined clusters by level of Type 2 inflammatory involvement in severe asthma (EMBER)
David Price, et al.
Biomarker-defined clusters of severe asthma patients were previously identified via hierarchical cluster analysis; a cluster of older females with low-to-medium Type 2 (T2) biomarkers was characterized. We aim to describe biomarker-defined clusters (blood eosinophil counts [BEC], FeNO, and serum IgE [IgE]) in severe asthma patients, and characterize T2-low asthma using a model-based approach to clustering.
Real-life biomarker response to anti-IL5 and anti- IgE therapies in severe asthma patients (IGNITE)
Sarah Burkill, et al.
Biologics (Bx) are known to decrease specific biomarker levels: anti-IL5 reduces blood eosinophils (BEC) and anti-IgE slightly reduces FeNO. Anti-IL5 and anti-IgE are thought to have limited effect on total IgE (IgE). We aim to To assess the proportions of severe asthma patients whose biomarkers (BEC, FeNO, and serum IgE) decrease following anti-IL5 and anti-IgE initiation.
The American Thoracic Society (ATS) Conference 2022
Impact of Initiating Biologics In Patients on Long-Term OCS Or Frequent Rescue Steroids (GLITTER)
Wenjia Chen, et al.
Real-world evidence on the effectiveness of biologic treatment in patients with asthma is limited. Our study assessed the effectiveness of initiating biologics in a large, international, real-world cohort of adult patients with severe asthma and high oral corticosteroid (OCS) exposure.
Prevalence of comorbidities in adults with severe asthma: results from the International Severe Asthma Registry (PRISM)
Ghislaine Scelo, et al.
Severe asthma accounts for 3-10% of the total population of patients with asthma. Comorbid conditions are common in patients with asthma and can complicate asthma management in multiple ways. Data are scarce on the prevalence and patterns of comorbidities in the severe asthma subpopulation.
*Abstracts presented as poster presentation
The European Respiratory Society (ERS) International Congress 2021
Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not (GLITTER)
Wenjia Chen, et al.
To describe the characteristics of an international severe asthma population with high exposure to oral corticosteroids (HOCS), comparing between those who initiated biologics and those that did not.
A summary of the live discussion can be found here!
The American Thoracic Society (ATS) Virtual Conference 2021
Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)
Mohsen Sadatsafavi, et al.
To describe the demographic and clinical characteristics of anti-IgE or anti–IL-5/5R users who were eligible for both modalities.
The Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science (TSANZSRS) 2021
The Respiratory Effectiveness Group (REG) Summit 2021
Exacerbations Are Associated With Lung Function Trajectory in a Broad Asthma Population in England, Scotland, and Wales 1950-2019
Seyi Soremekun, et al.
To assess the association between exacerbation burden and lung function decline in a broad asthma patient population.
Adapted encore from ATS 2020
The American Thoracic Society (ATS) Virtual Conference 2020
A Global Survey of Blood Eosinophil Distribution in Severe Asthma Patients: Data from the International Severe Asthma Registry (ISAR)
David Jackson, et al.
To describe the blood eosinophilic distribution in patients with severe asthma according to treatment, presence of nasal polyps, and age of onset.
Characterization of Eosinophilic and Non-Eosinophilic Severe Asthma Phenotypes and Proportion of Patients with These Phenotypes in the International Severe Asthma Registry (ISAR)
Luis Perez-de-Llano, et al.
To describe an algorithm to better characterize these phenotypes, and to assess the proportion of patients with eosinophilic and non-eosinophilic phenotypes in a large international cohort of patients with severe asthma.
The Impact of Exacerbation Burden on Lung Function Trajectory in a Broad UK Asthma Population: A Large Longitudinal Cohort Study
Seyi Soremekun, et al.
To assess the association between exacerbation burden and long-term lung function decline in a broad asthma patient population using longitudinal data.
The Respiratory Effectiveness Group (REG) 2020
(Cancelled due to COVID-19)
Cluster analysis according to biomarker profile differentiates clinical subgroups in the International Severe Asthma Registry (ISAR)
Eve Denton, et al.
This project describes biomarker overlap in a large, international severe asthma cohort, and cluster analysis according to biomarker levels yielded 5 distinct clusters.
The Demographic and Clinical Characteristics of Eosinophilic and non-Eosinophilic Phenotypes of Severe Asthma in International Severe Asthma Registry (ISAR)
Enrico Heffler, et al.
This study aimed to describe and compare the baseline demographic and clinical characteristics between EOS and non-EOS phenotypes of severe asthma.
Demographic and Clinical Characteristics of Patients with Severe Asthma who Continued, Stopped or Switched Biologic Therapy
Andrew Menzies-Gow, et al.
This study aimed to explore baseline clinical and demographic characteristics of a real-life severe asthma cohort according to patterns of biologic use.
The World Allergy Congress (WAC) 2019
Biomarker relatability in the International Severe Asthma Network
Eve Denton, et al.
This project describes biomarker overlap in a large, international severe asthma cohort as it relates to disease and patient characteristics.
The Asian Pacific Society of Respirology (APSR) Congress 2019
Demographic and Clinical Characteristics of Patients with Severe asthma in Japan and South Korea
Takashi Iwanaga, et al.
Here, the initial demographic and clinical data collected from Japan and South Korea between May 2018 and May 2019 are summarized.
International Severe Asthma Registry (ISAR): protocol for a global registry
David Price, et al.
Describing the need of having a global severe asthma registry.
The European Respiratory Society (ERS) International Congress 2019
Epidemiology of lung function in a global severe asthma population
Michael E. Wechsler, et al.
Describing post-bronchodilator (post-BD) lung function of adult severe asthma patients for an initial set of 5 countries (Ireland (IE), Italy (IT), South Korea (SK), the UK and the USA) using a standardized severe asthma definition.
The European Academy of Allergy and Clinical Immunology (EAACI) Congress 2019
Comparison of data fields captured by regional severe asthma registries participating in the International Severe Asthma Registry (ISAR)
Neva Eleangovan, et al. 2019; 1514.
Comparing data fields captured by national registries pre- and post-participation in ISAR. ISAR and local registries complement each other, the former providing a global view of severe asthma and the latter collecting ISAR core-, additional- and registry-specific-variables most relevant to local clinical management.
The American Thoracic Society (ATS) International Conference 2019
Cross-country comparison of demographic and clinical characteristics of patients managed in severe asthma services across UK, USA, Australia, South Korea and Italy
David Price, et al.; on behalf of the ISAR Study Group. 2019; 12959.
First characterization of the global adult severe asthma population (and cross country comparisons) in terms of key demographic and clinical variables.
The Respiratory Effectiveness Group (REG) Summit 2019
Overlap of biomarkers and T2 comorbidities in an international severe asthma population
Lakmini Bulathsinhala, et al. 2019; 09.
A description of key patient characteristics and biomarker clusters in a sample of the ISAR database, a first taste of how ISAR could be used to identify specific phenotypes of severe asthma.
The World Congress of Asthma (WCA) 2018
The Respiratory Effectiveness Group (REG) Summit 2018
Development of a Global Inventory of Severe Asthma Registries
Neva Eleangovan, et al. 2018
As the current severe asthma registry landscape is a collection of several national and regional registries with no comparisons of information collected made between them, we compared the data fields currently captured by severe asthma registries across the globe.